Literature DB >> 12012342

Combining mutations in HIV-1 protease to understand mechanisms of resistance.

Bhuvaneshwari Mahalingam1, Peter Boross, Yuan-Fang Wang, John M Louis, Christopher C Fischer, Jozsef Tozser, Robert W Harrison, Irene T Weber.   

Abstract

HIV-1 develops resistance to protease inhibitors predominantly by selecting mutations in the protease gene. Studies of resistant mutants of HIV-1 protease with single amino acid substitutions have shown a range of independent effects on specificity, inhibition, and stability. Four double mutants, K45I/L90M, K45I/V82S, D30N/V82S, and N88D/L90M were selected for analysis on the basis of observations of increased or decreased stability or enzymatic activity for the respective single mutants. The double mutants were assayed for catalysis, inhibition, and stability. Crystal structures were analyzed for the double mutants at resolutions of 2.2-1.2 A to determine the associated molecular changes. Sequence-dependent changes in protease-inhibitor interactions were observed in the crystal structures. Mutations D30N, K45I, and V82S showed altered interactions with inhibitor residues at P2/P2', P3/P3'/P4/P4', and P1/P1', respectively. One of the conformations of Met90 in K45I/L90M has an unfavorably close contact with the carbonyl oxygen of Asp25, as observed previously in the L90M single mutant. The observed catalytic efficiency and inhibition for the double mutants depended on the specific substrate or inhibitor. In particular, large variation in cleavage of p6(pol)-PR substrate was observed, which is likely to result in defects in the maturation of the protease from the Gag-Pol precursor and hence viral replication. Three of the double mutants showed values for stability that were intermediate between the values observed for the respective single mutants. D30N/V82S mutant showed lower stability than either of the two individual mutations, which is possibly due to concerted changes in the central P2-P2' and S2-S2' sites. The complex effects of combining mutations are discussed. Copyright 2002 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12012342     DOI: 10.1002/prot.10140

Source DB:  PubMed          Journal:  Proteins        ISSN: 0887-3585


  26 in total

1.  Pulsed EPR characterization of HIV-1 protease conformational sampling and inhibitor-induced population shifts.

Authors:  Zhanglong Liu; Thomas M Casey; Mandy E Blackburn; Xi Huang; Linh Pham; Ian Mitchelle S de Vera; Jeffrey D Carter; Jamie L Kear-Scott; Angelo M Veloro; Luis Galiano; Gail E Fanucci
Journal:  Phys Chem Chem Phys       Date:  2016-02-17       Impact factor: 3.676

2.  Molecular basis for substrate recognition and drug resistance from 1.1 to 1.6 angstroms resolution crystal structures of HIV-1 protease mutants with substrate analogs.

Authors:  Yunfeng Tie; Peter I Boross; Yuan-Fang Wang; Laquasha Gaddis; Fengling Liu; Xianfeng Chen; Jozsef Tozser; Robert W Harrison; Irene T Weber
Journal:  FEBS J       Date:  2005-10       Impact factor: 5.542

3.  Novel P2 tris-tetrahydrofuran group in antiviral compound 1 (GRL-0519) fills the S2 binding pocket of selected mutants of HIV-1 protease.

Authors:  Hongmei Zhang; Yuan-Fang Wang; Chen-Hsiang Shen; Johnson Agniswamy; Kalapala Venkateswara Rao; Chun-Xiao Xu; Arun K Ghosh; Robert W Harrison; Irene T Weber
Journal:  J Med Chem       Date:  2013-01-23       Impact factor: 7.446

4.  The role of select subtype polymorphisms on HIV-1 protease conformational sampling and dynamics.

Authors:  Xi Huang; Manuel D Britto; Jamie L Kear-Scott; Christopher D Boone; James R Rocca; Carlos Simmerling; Robert Mckenna; Michael Bieri; Paul R Gooley; Ben M Dunn; Gail E Fanucci
Journal:  J Biol Chem       Date:  2014-04-17       Impact factor: 5.157

5.  Elucidating the Interdependence of Drug Resistance from Combinations of Mutations.

Authors:  Debra A Ragland; Troy W Whitfield; Sook-Kyung Lee; Ronald Swanstrom; Konstantin B Zeldovich; Nese Kurt-Yilmaz; Celia A Schiffer
Journal:  J Chem Theory Comput       Date:  2017-10-09       Impact factor: 6.006

6.  Kinetic, stability, and structural changes in high-resolution crystal structures of HIV-1 protease with drug-resistant mutations L24I, I50V, and G73S.

Authors:  Fengling Liu; Peter I Boross; Yuan-Fang Wang; Jozsef Tozser; John M Louis; Robert W Harrison; Irene T Weber
Journal:  J Mol Biol       Date:  2005-10-21       Impact factor: 5.469

7.  Amino acid preferences for a critical substrate binding subsite of retroviral proteases in type 1 cleavage sites.

Authors:  Péter Bagossi; Tamás Sperka; Anita Fehér; János Kádas; Gábor Zahuczky; Gabriella Miklóssy; Péter Boross; József Tözsér
Journal:  J Virol       Date:  2005-04       Impact factor: 5.103

8.  Interactions of different inhibitors with active-site aspartyl residues of HIV-1 protease and possible relevance to pepsin.

Authors:  Jane M Sayer; John M Louis
Journal:  Proteins       Date:  2009-05-15

9.  Drug pressure selected mutations in HIV-1 protease alter flap conformations.

Authors:  Luis Galiano; Fangyu Ding; Angelo M Veloro; Mandy E Blackburn; Carlos Simmerling; Gail E Fanucci
Journal:  J Am Chem Soc       Date:  2009-01-21       Impact factor: 15.419

Review 10.  Resilience to resistance of HIV-1 protease inhibitors: profile of darunavir.

Authors:  Eric Lefebvre; Celia A Schiffer
Journal:  AIDS Rev       Date:  2008 Jul-Sep       Impact factor: 2.500

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.